IARC Working Group report on HPV vaccine trials

This 2014 report represents the views and expert opinions of an IARC Working Group that met in France in 2013. The Group reviewed the evidence as to whether it might be appropriate to use a virological end-point, rather than a disease end-point such as cervical intraepithelial neoplasia of grade 2 or worse (CIN2+), as the primary end-point for some future clinical efficacy trials, and the circumstances under which immunobridging trials might be sufficient for licensure. Read the full report, Primary end-points for prophylactic HPV vaccine trials, here.